While previous PKU intervention research has largely focused on pharmacological treatment of elevated Phe levels, the adaptation of evidence-based psychosocial therapy holds promise for addressing cognitive and psychological symptoms and significantly improving quality of life. Study goals include: (1) to demonstrate the efficacy and feasibility of a short-term skills-based intervention (Show Me FIRST) for anxiety and depression in adolescents with PKU, and (2) to further establish the psychometric validity of novel assessment measures recently developed by the Investigators that utilize ecological momentary assessment (EMA) to capture "in the moment" neurocognitive and psychological function. The Investigators propose to conduct a randomized controlled trial wherein 30 adolescents with PKU will be randomized to either an immediate intervention group or wait-list/delayed intervention group.
A sample of 30 adolescents (age 10-17) with PKU and a history of elevated anxiety and/or depression symptomatology will be recruited to participate in a randomized control trial. Following screening and informed consent, participants will be randomized to an immediate intervention group (n=15) or wait-list/delayed intervention group (n=15). Participants will receive the 10-week Show Me First program for treatment of anxiety and depression. Participants will complete extensive psychological and neurocognitive evaluations at three timepoints: Weeks 0, 11, and 22. The assessments and intervention will all be administered remotely via secure videoconference and cell-phone based applications.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
University of Missouri
Columbia, Missouri, United States
RECRUITINGPROMIS Anxiety & Depression scales
Patient-reported outcome (PRO) measure of anxiety \& depression symptoms
Time frame: Weeks 0, 11, & 22
Test My Brain phone-based EMA cognitive test
Performance-based measure of cognitive skill \& attention
Time frame: Weeks 0, 11, & 22
Behavior Rating Inventory of Executive Function (BRIEF)
Patient-reported outcome (PRO) measure of everyday symptoms of executive problems
Time frame: Weeks 0, 11, & 22
Blood Phenylalanine Levels
Time frame: Weeks 0, 5, 11, 16, & 22
ADHD Rating Scale - 4th version (ADHD-RS-IV)
Patient-reported outcome (PRO) measure of ADHD symptoms
Time frame: Weeks 0, 11, & 22
Executive Function, Attention, and Speed Symptom Inventory (EASSI) for PKU
Patient-reported outcome (PRO) measure of cognitive symptoms
Time frame: Weeks 0, 11, & 22
Rey Auditory Verbal Learning Test (Rey AVLT)
Performance-based measure of memory \& learning
Time frame: Weeks 0, 11, & 22
Stop Signal Task (SST)
Performance-based measure of inhibitory ability
Time frame: Weeks 0, 11, & 22
Revised Children's Anxiety and Depression Scale (RCADS)
Patient-reported outcome (PRO) measure of anxiety \& depression symptoms
Time frame: Weeks 0, 11, & 22
Behavior & Feelings Survey (BFS)
Patient-reported outcome (PRO) measure of internalizing \& externalizing problems
Time frame: Weeks 0, 11, & 22
Adolescent Insomnia Questionnaire (AIQ)
Patient-reported outcome (PRO) measure of sleep problems
Time frame: Weeks 0, 11, & 22
Global Impression Scale
Patient-reported outcome (PRO) measure of overall symptom severity and improvement
Time frame: Weeks 0, 11, & 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.